stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Studio di fase 3 randomizzato, in aperto, con Amivantamab in associazione a mFOLFOX6 o FOLFIRI versus Cetuximab in associazione a mFOLFOX6 o FOLFIRI nel trattamento in prima linea dei partecipanti con tumore al colon-retto sinistro non resecabile o metastatico con KRAS/NRAS e BRAF wild-type

Stato
Aperto - reclutamento in corso
Codice studio
61186372COR3001(OrigAMI 2)
Codice EudraCT
2024-513852-13
Sponsor/Promotore
Janssen-Cilag International NV
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Studio di fase II di combinazione di NMS-01940153E e Atezolizumab con o senza priming preventivo con decitabina a basse dosi per il trattamento di pazienti adulti con carcinoma epatocellulare (HCC) non resecabile precedentemente trattati con inibitori del checkpoint Iimmunitario

Stato
Aperto - reclutamento in corso
Codice studio
MPSA-153-002
Codice EudraCT
2024-516737-12-00
Sponsor/Promotore
NERVIANO MEDICAL SCIENCES SRL
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Studio randomizzato di fase III di valutazione della terapia con gemcitabina e nab-PAclitaxel come chemioterapia di maNTEnimento rispetto alla cONtinuazione di mFOLFIRINOX come chemioterapia di prima linea in pazienti con tumore del pancreas in stadio avanzato: studio PANThEON

Stato
Autorizzato - In attesa di apertura
Codice studio
PANTHEON
Codice EudraCT
2024-515214-41-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Meccanismi di immunosorveglianza nel carcinoma del retto – Microambiente immunitario nel cancro del retto, individuazione dei markers prognostici (IMMUNOREACT)

Stato
Aperto - reclutamento in corso
Codice studio
IMMUNOREACT_ ripresentazione
Codice EudraCT
NP
Sponsor/Promotore
Azienda Ospedaliera di Padova
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Sperimentazione randomizzata in aperto sull’efficacia e la sicurezza di zanidatamab con terapia standard rispetto alla sola terapia standard per il tumore delle vie biliari avanzato HER2-positivo

Stato
Aperto - reclutamento in corso
Codice studio
JZP598-302-01
Codice EudraCT
2023-508219-21-00
Sponsor/Promotore
Jazz Pharmaceuticals Ireland Limited
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after preoperative chemoTherapy and radical surgerY: the TRINITY study.

Stato
Aperto - reclutamento in corso
Codice studio
TRINITY
Codice EudraCT
2023-506662-31-00
Sponsor/Promotore
GONO Gruppo Oncologico Nord Ovest
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top